AR084158A1 - Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas - Google Patents

Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas

Info

Publication number
AR084158A1
AR084158A1 ARP110104542A ARP110104542A AR084158A1 AR 084158 A1 AR084158 A1 AR 084158A1 AR P110104542 A ARP110104542 A AR P110104542A AR P110104542 A ARP110104542 A AR P110104542A AR 084158 A1 AR084158 A1 AR 084158A1
Authority
AR
Argentina
Prior art keywords
formulations
poloxamer
mitigate
immunogenic compositions
agmation
Prior art date
Application number
ARP110104542A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR084158A1 publication Critical patent/AR084158A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulaciones que mitigan la agregación inducida por agitación de composiciones inmunogénicas particularmente aquellas que tienen conjugados de polisacárido-proteína. Específicamente, las formulaciones comprenden un poloxámero dentro del intervalo de peso molecular de 1.100 a 17.400 que proporciona ventajas significativas con respecto a tensioactivos usados previamente que incluyen polisorbato 80. En una realización, proporciona una composición inmunogénica multivalente que tiene 15 conjugados de polisacárido-proteína diferentes y un poloxámero. Cada conjugado consiste en un polisacárido capsular preparado a partir de un serotipo diferente de Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F o 33F) conjugado a una proteína transportadora, preferentemente CRM197.Reivindicación 2: El poloxámero de la reivindicación 1 que tiene un peso molecular en el intervalo de 7.500 a 15.000.
ARP110104542A 2010-12-10 2011-12-05 Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas AR084158A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42196010P 2010-12-10 2010-12-10

Publications (1)

Publication Number Publication Date
AR084158A1 true AR084158A1 (es) 2013-04-24

Family

ID=46207464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104542A AR084158A1 (es) 2010-12-10 2011-12-05 Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas

Country Status (13)

Country Link
US (1) US20130273098A1 (es)
EP (1) EP2648506A1 (es)
JP (1) JP2014502595A (es)
KR (1) KR20140005892A (es)
CN (1) CN103391714A (es)
AR (1) AR084158A1 (es)
AU (1) AU2011338723A1 (es)
BR (1) BR112013012626A2 (es)
CA (1) CA2819366A1 (es)
MX (1) MX2013006539A (es)
RU (1) RU2013131795A (es)
TW (1) TW201304803A (es)
WO (1) WO2012078482A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
PL2575870T3 (pl) * 2010-06-04 2017-05-31 Wyeth Llc Preparaty szczepionek
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014027302A1 (en) * 2012-08-16 2014-02-20 Pfizer Inc. Glycoconjugation processes and compositions
CN103623401A (zh) * 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
MX365331B (es) 2013-01-17 2019-05-29 Arsanis Biosciences Gmbh Anticuerpo específico contra e. coli mdr.
CN104069488A (zh) * 2013-03-29 2014-10-01 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
EP3096785B1 (en) * 2014-01-21 2020-09-09 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3583947B1 (en) * 2014-01-21 2023-10-11 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
CA2940547C (en) 2014-02-24 2021-01-05 Glycovaxyn Ag Novel polysaccharide and uses thereof
WO2016055957A1 (en) * 2014-10-09 2016-04-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof
US10729780B2 (en) * 2015-06-08 2020-08-04 Serum Institute Of India Private Ltd. Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof
PE20180657A1 (es) * 2015-07-21 2018-04-17 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US11197921B2 (en) 2017-01-31 2021-12-14 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
AU2018225083B2 (en) * 2017-02-24 2023-06-01 Merck Sharp & Dohme Llc Pneumococcal conjugate vaccine formulations
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
WO2018156491A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
US20200360500A1 (en) * 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
CN117736348A (zh) * 2017-09-07 2024-03-22 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用
CN111278458A (zh) * 2017-10-25 2020-06-12 默沙东公司 佐剂疫苗
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
US11648317B2 (en) * 2018-04-13 2023-05-16 Genentech, Inc. Stable anti-CD79B immunoconjugate formulations
US20210252125A1 (en) 2018-04-30 2021-08-19 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
JOP20210148A1 (ar) 2018-12-19 2023-01-30 Merck Sharp & Dohme تركيبات تشتمل على متقارنات بولي سكاريد-بروتين للمكورات العقدية الرئوية وطرق استخدامها
EA202192390A1 (ru) 2019-03-18 2021-12-03 Янссен Фармасьютикалз, Инк. Биоконъюгаты полисахаридных о-антигенов e.coli, способы их получения и способы их применения
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
CA3148928A1 (en) * 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1320542B9 (en) * 2000-08-08 2007-09-12 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
WO2008051245A2 (en) * 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
CN101378782A (zh) * 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100203137A1 (en) * 2007-06-04 2010-08-12 Mario Contorni Formulation of meningitis vaccines
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
AU2009296458A1 (en) * 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same

Also Published As

Publication number Publication date
MX2013006539A (es) 2013-07-22
EP2648506A1 (en) 2013-10-16
TW201304803A (zh) 2013-02-01
JP2014502595A (ja) 2014-02-03
WO2012078482A1 (en) 2012-06-14
RU2013131795A (ru) 2015-01-20
CN103391714A (zh) 2013-11-13
KR20140005892A (ko) 2014-01-15
CA2819366A1 (en) 2012-06-14
US20130273098A1 (en) 2013-10-17
AU2011338723A1 (en) 2013-05-30
BR112013012626A2 (pt) 2016-07-19

Similar Documents

Publication Publication Date Title
AR084158A1 (es) Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
AR116043A2 (es) Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente
BR112020004471A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
BR112020004509A8 (pt) Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
PH12015501269B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
PH12014502843B1 (en) Polyvalent pneumococcal polysaccharide-protein conjugate composition
MX2022009928A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CO7461130A2 (es) Composición multivalente de conjugados de proteína-polisacárido neumococico
WO2011151760A3 (en) Streptococcus pneumoniae vaccine formulations
CY1112777T1 (el) Πολυδυναμη συνθεση συζευγματος πνευμονιοκοκκικου πολυσακχαριτη-πρωτεϊνης
EA201990126A1 (ru) Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция
AR092897A1 (es) Composiciones inmunogenicas
TH128171A (th) องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน
TH171459A (th) "องค์ประกอบมัลติวาเลนท์ นิวโมคอกคัสโพลีแซคคาไรด์-โปรตีน คอนจูเกต"
TH160962A (th) "องค์ประกอบมัลติวาเลนท์ นิวโมคอกคัสโพลีแซคคาไรด์-โปรตีน คอนจูเกต"
AR093161A1 (es) Composicion de conjugados polisacarido-proteina neumococicos multivalente
TH160962B (th) "องค์ประกอบมัลติวาเลนท์ นิวโมคอกคัสโพลีแซคคาไรด์-โปรตีน คอนจูเกต"
TH128171B (th) องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน

Legal Events

Date Code Title Description
FB Suspension of granting procedure